Literature DB >> 17557292

Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends.

Peter Jepsen1, Hendrik Vilstrup, Robert E Tarone, Søren Friis, Henrik Toft Sørensen.   

Abstract

Hepatocellular carcinoma (HCC) incidence rates vary by gender, age, time and place. Geographic differences in gender-, age- and time-specific HCC incidence rates may improve the understanding of HCC risk factors. We computed annual standardized HCC incidence rates for the United States (U.S.) 1978-2004 and for Denmark 1978-2003. Among U.S. white men aged 45-59 the HCC incidence rates were comparable to the Danish rates until 1995, but more than tripled over the following 8 years to become over 2.5-fold higher than the Danish rate by 2003, with an additional small increase in 2004. HCC rates in black U.S. men aged 45-59 also increased sharply after 1995. Among women aged 45-59 the U.S. HCC rates were elevated in recent years, but did not show the sharp increase after 1995 observed among men; the Danish rates showed a decreasing trend throughout 1978-2003. U.S. rates in the 60-74 years age groups showed a protracted and gradual increase with no evidence of a sharp increase after 1995. In the 60-74 years age group, rates for Danish men were comparable to those for U.S. white men, but rates for Danish women decreased. The U.S. prevalence rates of hepatitis C virus (HCV) infection are 2.1 and 1.1% for men and women, respectively, the Danish 0.2%. The disparity in HCV prevalence is the most likely explanation for the differences between Danish and U.S. trends in HCC incidence. Intravenous drug use and blood transfusions are the major sources of HCV, and we suggest that increased HCV infection prevalence among Vietnam era military veterans may contribute to the earlier and steeper HCC incidence increase for U.S. men than for U.S. women.

Entities:  

Mesh:

Year:  2007        PMID: 17557292     DOI: 10.1002/ijc.22860

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients.

Authors:  Seoung-Ae Lee; Ki-Jeong Kim; Dong-Won Kim; Bum-Joon Kim
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

Review 2.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

Review 3.  Current state of nonsurgical therapies for cholangiocarcinoma.

Authors:  Volker Brass; Jan B Kuhlmann; Hubert E Blum
Journal:  Hepat Oncol       Date:  2013-12-20

4.  The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma.

Authors:  Takeki Uehara; Igor P Pogribny; Ivan Rusyn
Journal:  Curr Protoc Pharmacol       Date:  2014-09-02

Review 5.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 6.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma.

Authors:  Masato Tsuchiya; Joel S Parker; Hiroshi Kono; Masanori Matsuda; Hideki Fujii; Ivan Rusyn
Journal:  Mol Cancer       Date:  2010-04-09       Impact factor: 27.401

8.  Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-11

9.  Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis.

Authors:  Takeki Uehara; Garrett R Ainslie; Kristi Kutanzi; Igor P Pogribny; Levan Muskhelishvili; Takeshi Izawa; Jyoji Yamate; Oksana Kosyk; Svitlana Shymonyak; Blair U Bradford; Gary A Boorman; Ramon Bataller; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2013-01-03       Impact factor: 4.849

10.  Surveillance and Diagnosis of Hepatocellular Carcinoma.

Authors:  Paul Fitzmorris; Ashwani K Singal
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.